Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection

Completed

• Conditions: Hepatitis C Infection

• Registration Number: NCT01771653
• Lead Sponsor: Southern Illinois University

Brief Summary

The purpose of this observational study is to compare two approved treatment regimen(s) containing boceprevir and telaprevir, as part of standard of care for the treatment of hepatitis C.

Detailed Description

The objective of the study is to compare the effect of adding 2 oral hepatitis C virus (HCV) protease inhibitors, telaprevir versus boceprevir, as part of current standard treatment regimen with (pegylated-interferon-alpha + ribavirin) for HCV Genotype-1 infection. Data will be obtained from medical records of consenting patients.

Study Timeline

• Study Start: 2011-09
• Study First Submitted: 2013-01-16
• Study First Submitted QC: 2013-01-17
• Study First Posted: 2013-01-18
• Primary Completion: 2015-07
• Study Completion: 2015-07
• Status Verified: 2016-01
• Last Update Submitted: 2016-01-15
• Last Update Posted: 2016-01-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

• Age - 18-64 years
• HCV genotype 1
• HCV RNA >100,000
• Liver biopsy within 5 years before enrollment
• Absolute neutrophil count of at least 1200 per cubic millimeter
• Platelet count of at least 90,000 per cubic millimeter
• Hemoglobin level of at least 12 g per deciliter
• Signed informed consent and Health Insurance Portability and Accountability Act (HIPAA) forms

Exclusion Criteria

• HCV genotypes other than genotype 1
• Immunocompromised conditions including HIV, transplant or immunosuppressive drugs
• Decompensated liver disease or hepatocellular carcinoma
• Any other types of active cancer
• Active autoimmune disorders
• Major psychiatric disorders
• Active drug or alcohol use
• Pregnancy or lactation
• Patients with allergy to any of the drugs used in this study
• Drugs that may interact with boceprevir or telaprevir as listed in the package insert

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Virologic Response	up to 96 weeks post treatment	Sustained Virologic Response (SVR) rates will be compared between the two arms of treatment through measured HCV RNA levels after 24 weeks, 48 weeks and 96 weeks after completion of treatment.

Secondary Outcome Measures

Name	Time	Method
Effect of baseline variables on treatment outcome	24, 48, and 96 weeks post treatment	Analyze the effects of baseline variables on treatment outcome between the two groups- age, race, social economic status.
Adverse events	24, 48, and 96 weeks post treatment	Comparison of rates and severity of adverse events between the two study arms

Trial Locations

Locations (1)

Southern Illinois University School of Medicine; 🇺🇸 Springfield, Illinois, United States